Research and analysis

ACMD review of the evidence on the use and harms of diphenidine

The Advisory Council on the Misuse of Drugs has undertaken a review of the evidence on the use and harms of diphenidine and other related substances.

• From: Advisory Council on the Misuse of Drugs
• Published: 25 May 2023
• Last updated: 26 May 2023 — See all updates

Documents

ACMD review of the evidence on the use and harms of diphenidine (accessible)

HTML

ACMD review of the evidence on the use and harms of diphenidine

PDF, 417 KB, 36 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Letter from ACMD to the Home Secretary: ACMD review of diphenidine (accessible)

HTML

Letter from ACMD to the Home Secretary: ACMD review of diphenidine

PDF, 149 KB, 4 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

In 2022 the Advisory Council on the Misuse of Drugs (ACMD) was commissioned to give advice on the appropriate classification and scheduling of diphenidine under the Misuse of Drugs Act 1971. Diphenidine was added to schedule II of the Convention on Psychotropic Substances of 1971 during the 64th Commission on Narcotic Drugs (CND) meeting in April 2021.

The ACMD has written this report describing the use and harms of diphenidine and related substances ephenidine, methoxyphenidine, fluorolintane and isophenidine. The report provides recommendations of their classification and scheduling, following a thorough review of the evidence available.

Published 25 May 2023
Last updated 26 May 2023 + show all updates

1. 26 May 2023

   Accessible versions of the report and letter added.

2. 25 May 2023

   First published.